Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
What are your preferred echocardiographic parameters and goals for weaning RVAD support?
Related Questions
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
What is your approach when a patient has concomitant acute decompensated heart failure and rapid atrial fibrillation?
How do you approach caring for patients admitted with decompensated CHF, but who also exhibit hypotension and do not have overt signs of hypervolemia on exam?
Can mavacamten be considered for patients with HCM and ongoing dyspnea in setting of an elevated LVEDP but without significant LV outflow obstruction on imaging?
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
How do you weigh the benefit of urinary catheter placement for strict I/O measurement with the risk of avoidable CAUTI?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
For patients admitted with acute decompensated heart failure, do you wait until the patient is euvolemic before ordering a TTE?
Given findings from the LIFE trial, are there any benefits in using Entresto over valsartan alone in HFrEF patients?
